|
|
 |
| Professor |
Office:
919-843-4595 |
| |
| |
| |
| |
| We
are investigating the role of Epstein-Barr virus (EBV) in
the development of malignancies including lymphoma, nasopharyngeal
carcinoma and gastric cancer. Molecular and immunologic techniques
are used to evaluate EBV gene expression, to localize viral
products to particular cells in human tissues, and to evaluate
interactions between EBV and cellular gene products. Gene
expression profiling is being explored as a means of determining
mechanisms of tumorigenesis and to categorize lesions in
a way that can be used to improve diagnosis or management
of affected patients. Tests currently used to assist in diagnosis
and monitoring of EBV-related malignancies include EBV viral
load assays to monitor tumor burden in blood and cerebrospinal
fluid samples, and EBER in situ hybridization to detect and
localize EBV in paraffin embedded tissues or cytologic specimens.
A related focus of clinical research is on the use of molecular
genetic technology in diagnostic pathology, with the aim
of improving diagnosis and treatment of patients with cancer,
inherited disease, or infectious disease.
Unique Technical and Clinical Research Capabilities/Instrumentation:
Facilities available for DNA or RNA extraction and storage;
Southern blot, real-time PCR and rtPCR, and in situ hybridization,
targeting a wide variety of clinically-relevant human genes
or infectious agents. For information on clinical laboratory
tests and training opportunities in Molecular Genetics, visit
our web
site.
Gulley
Research Lab Services (available to other
investigators)
|
| |
| |
| Gulley ML, Braziel RM, Halling KC, Hsi ED, Kant JA, Nikiforova MN, Nowak JA, Ogino S, Oliveira A, Polesky HF, Silverman L, Tubbs RR, Van Deerlin VM, Vance GH, Versalovic J: Clinical Laboratory Reports in Molecular Pathology, Arch Pathol Lab Med, 131:852-863, 2007. |
| |
| Gulley ML: Public policy recommendations for oversight of molecular laboratory tests. NC Med J 68:109-111, 2007. |
| |
| Thorne LB, Civalier C, Booker J, Fan H, Gulley ML: Analytic Validation of a Quantitative Real-Time PCR Assay to Measure CMV Viral Load in Whole Blood, Diagn Molec Pathol, 16:73-80, 2007. |
| |
| Nikiforova MN, Hsi E, Braziel RM, Gulley ML, Leonard DG, Nowak JA, Tubbs RR, Vance GH, VanDeerlin VM, Molecular Pathology Resource Committee, College of American Pathologists: Detection of clonal IGH gene rearrangements: summary of molecular oncology surveys of the College of American Pathologists. Arch Pathol Lab Med 131:185-9, 2007. |
| |
| Ogino S, Gulley ML, den Dunnen JT, Wilson RB: Standard Mutation Nomenclature in Molecular Diagnostics: Practical and Educational Challenges. J Molec Diagn, 9:1-6, 2007. |
| |
| Gulley ML, Fan H, Elmore SH: Validation of Roche LightCycler EBV Quantification Reagents in a Clinical Laboratory Setting. J Molec Diagn, 8:589-597, 2006. |
| |
| Ryan JL, Kaufmann WK, Raab-Traub N, Oglesbee SE, Carey LA, Gulley ML: Clonal evolution of lymphoblastoid cell lines. Lab Invest 86:1193-1200, 2006. |
| |
| Shaw M, Groben P, Warren S, Gulley ML: No evidence of Epstein-Barr virus association with Merkel cell carcinoma, J Cutaneous Pathol, 33:624-628, 2006. |
| |
| Scanga L, Chaing S, Powell C, Aylsworth AS, Harrell LJ, Henshaw HG, Civalier CJ, Thorne LB, Weck K, Booker J, Gulley ML: Diagnosis of congenital human cytomegalovirus Infection by PCR of viral DNA from dried blood spots on perinatal cards. J Molec Diagn, 8:240-245, 2006. |
| |
| Fan H, Civalier C, Booker J, Gulley ML, Prior TW, Farber RA: Detection of Common Disease-Causing Mutations in Mitochondrial DNA (MELAS MTTL1 3243 A>G and MERRF MTTK 8344A>G) by Real-Time PCR. J Molec Diagn, 8:277-281, 2006. |
| |
| Libby EN, Booker JK, Gulley ML, Garcia D, Moll S: False negative factor V Leiden genetic testing in a patient with recurrent deep venous thrombosis. Am J Hematol, 81:284-9, 2006. |
| |
| Kilpatrick SE, Bergman S, Pettenati MJ, Gulley ML: The usefulness of cytogenetics in fine needle aspirates for the histologic subtyping of sarcomas. Human Pathol, 19:815-819, 2006. |
| |
| Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC: Anti-CD70 antibodies: a potential treatment for CD70-expressing lymphomas. Molec Cancer Therapeutics, 4:2037, 2005. |
| |
| Keegan THM, Glaser SL, Clarke CA, Gulley ML, Craig FE, DiGiuseppe JA, Dorfman RF, Mann RB, Ambinder RF: Epstein-Barr virus as a marker of survival after Hodgkin Lymphoma: a population-based study, J Clin Oncol, 23:7604-13, 2005. |
| |
| Yang XR, Goldstein AM, Chen CJ, Rabkin CS, Chen JY, Cheng YJ, Hsu WL, Sun B, Diehl SR, Liu MY, Walters M, Shao W, Ortiz-Conde BA, Whitby D, Elmore SH, Gulley ML, Hildesheim A: Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. Int J Cancer, 118:780-4, 2005. |
| |
| Hong GK, Kumar P, Wang L, Damania B, Gulley ML, Delecluse HJ, Polverini PJ, Kenney SC: Epstein-Barr Virus Lytic Infection is Required for Efficient Production of the Angiogenesis Factor VEGF in Lymphoblastoid Cell Lines. J Virol, 79:13984-92, 2005. |
| |
| Hong GK, Gulley ML, Feng WH, Delecluse HJ, Kenney SC: Epstein-Barr Virus Lytic Infection Contributes to Tumorigenesis in a SCID Mouse Model of Lymphoma. J Virol, 79:13993-4003, 2005. |
| |
| Thorne LB, Ryan JL, Elmore SH, Glaser SL, Gulley ML: Real-time PCR measures Epstein-Barr virus DNA in archival breast adenocarcinomas. Diagn Molec Pathol 14:29-33, 2005. |
| |
| Fan H, Kim SC, Chima CO, Israel BF, Lawless KM, Eagan PA, Elmore S, Moore DT, Schichman SA, Swinnen LJ, Gulley ML. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol, 75:59-69, 2005. |
| |
| |
|
| |
| |
| |
|
|
